| Literature DB >> 29607322 |
N Cable1, A Hiyoshi2, N Kondo3, J Aida4, H Sjöqvist2,5, K Kondo6.
Abstract
We examined correlating clinical biomarkers for the physical aspect of frailty among community-dwelling older adults in Japan, using Japanese Gerontological Evaluation Study (JAGES). We used information from the JAGES participants (N = 3,128) who also participated in the community health screening in 2010. We grouped participants' response to the Study of Osteoporotic Fracture (SOF) Frailty Index into robust (=0), intermediate frail (=1), and frail (=2+) ones to indicate physical aspect of frailty. Independent of sex and age, results from multinomial logistic regression showed above normal albumin and below normal HDL and haemoglobin levels were positively associated with intermediate frail (RRR = 1.99, 95% CI = 1.22-3.23; RRR = 1.36, 95% CI = 1.33-1.39; RRR = 1.36, 95% CI = 1.23-1.51, resp.) and frail cases (RRR = 2.27, 95% CI = 1.91-2.70; RRR = 1.59, 95% CI = 1.51-1.68; RRR = 1.40, 95% CI = 1.28-1.52, resp.). Limited to women, above normal Hb1Ac level was similarly associated with intermediate frail and frail cases (RRR = 1.18, 95% CI = 1.02, 1.38; RRR = 2.56, 95% CI = 2.23-2.95, resp.). Use of relevant clinical biomarkers can help in assessment of older adults' physical aspect of frailty.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29607322 PMCID: PMC5828560 DOI: 10.1155/2018/5362948
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Sample characteristics, numbers of participants, and proportions (%) by levels (below normal, normal, and above normal) of study biomarkers according to the SOF Frailty category (N = 3,128).
| SOF Frailty Index category | |||
|---|---|---|---|
| Robust | Intermediate | Frail | |
| ( | ( | ( | |
|
| |||
|
| |||
| Age in year, mean (SD) | 70.9 (4.8) | 71.7 (5.3) | 73.6 (6.4) |
| Gender | |||
| Men | 732 (49.1) | 609 (40.8) | 151 (10.1) |
| Women | 702 (42.9) | 671 (41.0) | 263 (16.1) |
|
| |||
| HbA1c (%): men | |||
| Below normal | 81 (53.6) | 53 (35.1) | 17 (11.3) |
| Normal | 527 (48.3) | 454 (41.7) | 109 (10.0) |
| Above normal | 121 (48.8) | 101 (40.7) | 26 (10.5) |
| HbA1c (%): women | |||
| Below normal | 120 (40.4) | 131 (44.1) | 46 (15.5) |
| Normal | 532 (44.8) | 482 (40.6) | 174 (14.6) |
| Above normal | 53 (34.4) | 59 (38.3) | 42 (27.3) |
| HDL (mg/dL) | |||
| Below normal | 147 (38.3) | 174 (45.3) | 63 (16.4) |
| Normal | 1255 (46.7) | 1087 (40.4) | 347 (12.9) |
| Above normal | 32 (58.2) | 19 (34.5) | 4 (7.3) |
| LDL (mg/dL) | |||
| Below normal | 25 (45.5) | 16 (29.1) | 14 (25.5) |
| Normal | 1306 (45.7) | 1172 (41.1) | 377 (13.2) |
| Above normal | 103 (47.2) | 92 (42.2) | 23 (10.6) |
| Triglyceride (mg/dL) | |||
| Below normal | 5 (35.7) | 8 (57.1) | 1 (7.1) |
| Normal | 1023 (46.4) | 883 (40.1) | 297 (13.5) |
| Above normal | 406 (44.6) | 389 (42.7) | 116 (12.7) |
| Haemoglobin (g/dL) | |||
| Below normal | 259 (38.3) | 297 (43.9) | 120 (17.8) |
| Normal | 1118 (48.0) | 935 (40.1) | 277 (11.9) |
| Above normal | 57 (46.7) | 48 (39.3) | 17 (13.9) |
| Serum albumin (g/dL) | |||
| Below normal | 89 (36.0) | 89 (36.0) | 69 (27.9) |
| Normal | 1335 (46.8) | 1176 (41.2) | 341 (12.0) |
| Above normal | 10 (34.5) | 15 (51.7) | 4 (13.8) |
| Creatinine (mg/dL) | |||
| Below normal | 34 (43.6) | 34 (43.6) | 10 (12.8) |
| Normal | 1273 (46.3) | 1117 (40.6) | 362 (13.2) |
| Above normal | 127 (42.6) | 129 (43.3) | 42 (14.1) |
| Uric acid (mg/dL) | |||
| Below normal | 27 (45.0) | 25 (41.7) | 8 (13.3) |
| Normal | 1252 (46.0) | 1120 (41.1) | 352 (12.9) |
| Above normal | 155 (45.1) | 135 (39.2) | 54 (15.7) |
| Urine | |||
| Protein absence | 1213 (45.9) | 1083 (41.0) | 344 (13.0) |
| Protein: trace or positive | 221 (45.3) | 197 (40.4) | 70 (14.3) |
| eGFR (mL/min/1.73 m2) | |||
| Normal | 1120 (47.0) | 963 (40.4) | 300 (12.6) |
| Above normal | 314 (42.1) | 317 (42.6) | 114 (15.3) |
Relative risk ratio (RRR) with 95% CI in parentheses for intermediate frail and frail by biomarker levels among the JAGES study participants (N = 3,128).
| Biomarkers | Robust | Intermediate frail | Frail | ||
|---|---|---|---|---|---|
| Model 1 | Model 2b | Model 1 | Model 2b | ||
| HbA1c (male) | |||||
| Below normal | Reference | 0.85 (0.76, 0.96) | 0.86 (0.73, 1.02) | 1.28 (0.50, 3.30) | 1.21 (0.46, 3.18) |
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 0.99 (0.72, 1.36) | 0.99 (0.70, 1.39) | 1.04 (0.75, 1.43) | 0.99 (0.76, 1.29) |
| HbA1c (female) | |||||
| Below normal | Reference | 1.19 (1.12, 1.26) | 1.22 (1.13, 1.31) | 1.21 (0.86, 1.72) | 1.20 (0.81, 1.78) |
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 1.21 (1.07, 1.36) | 1.18 (1.02, 1.38) | 2.63 (2.22, 3.11) | 2.56 (2.23, 2.95) |
| HDL | |||||
| Below normal | Reference | 1.34 (1.20, 1.48) | 1.36 (1.23, 1.51) | 1.44 (1.29, 1.62) | 1.40 (1.28, 1.52) |
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 0.70 (0.51, 0.96) | 0.69 (0.46, 1.04) | 0.50 (0.26, 0.97) | 0.48 (0.26, 0.89) |
| LDL | |||||
| Below normal | Reference | 0.74 (0.51, 1.09) | 0.66 (0.41, 1.08) | 2.34 (1.56, 3.50) | 1.79 (1.21, 2.64) |
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 1.02 (0.68, 1.53) | 1.03 (0.66, 1.60) | 0.82 (0.63, 1.06) | 0.94 (0.76,1.15) |
| Triglyceride | |||||
| Below normal | Reference | 1.82 (0.69, 4.82) | 2.09 (0.70, 6.26) | 0.73 (0.51, 1.04) | 0.66 (0.47,0.93) |
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 1.10 (0.99, 1.22) | 1.05 (0.97, 1.14) | 0.92 (0.74, 1.14) | 0.88 (0.71,1.08) |
| Haemoglobin | |||||
| Below normal | Reference | 1.34 (1.29, 1.39) | 1.36 (1.33, 1.39) | 1.75 (1.57, 1.96) | 1.59 (1.51,1.68) |
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 1.02 (0.96, 1.09) | 1.01 (0.96, 1.07) | 1.27 (0.69, 2.34) | 1.28 (0.81,2.02) |
| Serum albumin | |||||
| Below normal | Reference | 1.06 (0.75, 1.48) | 0.96 (0.68, 1.36) | 2.49 (1.76, 3.52) | 2.06 (1.48,2.87) |
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 1.85 (1.18, 2.88) | 1.99 (1.22, 3.23) | 2.07 (1.50, 2.85) | 2.27 (1.91,2.70) |
| Creatinine | |||||
| Below normal | Reference | 1.21 (0.61, 2.42) | 1.27 (0.60, 2.66) | 1.35 (0.66, 2.74) | 1.32 (0.63,2.80) |
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 1.08 (1.02, 1.15) | 0.96 (0.82, 1.12) | 0.94 (0.79, 1.14) | 0.71 (0.63,0.80) |
| Uric acid | |||||
| Below normal | Reference | 1.09 (0.78, 1.51) | 1.08 (0.86, 1.36) | 1.30 (0.93, 1.80) | 1.10 (0.75,1.59) |
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 0.90 (0.70, 1.15) | 0.85 (0.65, 1.10) | 0.92 (0.88, 0.96) | 0.88 (0.77,1.02) |
| Urine | |||||
| Protein: absent | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Protein: trace or positive | Reference | 1.02 (1.00, 1.05) | 1.02 (0.99, 1.04) | 1.24 (1.08, 1.42) | 1.19 (1.05,1.36) |
| eGFR | |||||
| Normal | Reference | 1.00 | 1.00 | 1.00 | 1.00 |
| Above normal | Reference | 1.11 (1.04, 1.18) | 1.12 (0.99, 1.26) | 1.11 (0.98, 1.25) | 1.17 (0.95,1.44) |
Model 1: adjusted for age and sex for biomarkers other than HbA1c; adjusted for age for HbA1c. Model 2: Model 1 + all biomarkers. bFor Hb1Ac, sex interaction is included and estimates are provided by each gender. Note. A robust sandwich estimator for standard errors was used to adjust data clustering within municipalities.